---
title: "Brain-computer interface concept stocks surged, Innovative Medical rose nearly 9% as the first invasive brain-computer interface medical device was approved for market launch"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/278991952.md"
description: "On March 13th, the A-share market's brain-computer interface concept stocks collectively surged, with Innovative Medical rising nearly 9%. The National Medical Products Administration approved the registration application for the implantable brain-computer interface medical device from BoRuiKang Medical Technology, marking the entry of the world's first invasive brain-computer interface medical device into clinical application. This product significantly improves patients' hand grip ability and enhances their quality of life through minimally invasive implantation and wireless power supply technology"
datetime: "2026-03-13T06:17:17.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/278991952.md)
  - [en](https://longbridge.com/en/news/278991952.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/278991952.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/278991952.md) | [繁體中文](https://longbridge.com/zh-HK/news/278991952.md)


# Brain-computer interface concept stocks surged, Innovative Medical rose nearly 9% as the first invasive brain-computer interface medical device was approved for market launch

On March 13, the brain-computer interface concept stocks in the A-share market collectively surged, with Innovative Medical rising nearly 9%, Yinkang Life, Sanbo Brain Science, and Aipeng Medical rising over 5%, and Daoshi Technology, Saily Medical, Nanjing Panda, and Yanshan Technology rising over 3%.

In terms of news, recently, the National Medical Products Administration approved the registration application for the innovative product of the implanted brain-computer interface hand movement function compensation system by Boruikang Medical Technology (Shanghai) Co., Ltd., achieving the global first launch of brain-computer interface medical devices (core stocks) and marking the entry of the world's first invasive brain-computer interface medical device into the clinical application stage. This product uses minimally invasive implantation outside the dura mater and wireless power supply communication technology. Clinical trial results show that subjects achieved a significant improvement in hand grasping ability through this product, thereby improving the quality of life for patients.

More exclusive planning and expert columns in the stock channel, free access \>\>

### Related Stocks

- [E Fund CSI 300 Health Care ETF (512010.CN)](https://longbridge.com/en/quote/512010.CN.md)
- [GF CSI All Share Health Care ETF (159938.CN)](https://longbridge.com/en/quote/159938.CN.md)
- [GF CSI HK Innovative Drugs Industry ETF(QDII) (513120.CN)](https://longbridge.com/en/quote/513120.CN.md)
- [E Fund CSI Biotechnology Theme ETF (159837.CN)](https://longbridge.com/en/quote/159837.CN.md)
- [China Universal 800 Health Care ETF (159929.CN)](https://longbridge.com/en/quote/159929.CN.md)
- [China Merchants CSI Biotechnology Theme ETF (159849.CN)](https://longbridge.com/en/quote/159849.CN.md)
- [Innovative Medical (002173.CN)](https://longbridge.com/en/quote/002173.CN.md)
- [Minsheng Royal CSI Biotechnology Theme ETF (516930.CN)](https://longbridge.com/en/quote/516930.CN.md)
- [Guotai SSE STAR Brand Name Drug ETF (589720.CN)](https://longbridge.com/en/quote/589720.CN.md)
- [ChinaAMC CSI Biotechnology Theme ETF (516500.CN)](https://longbridge.com/en/quote/516500.CN.md)
- [ChinaAMC SSE Health Care ETF Initiating Fund (510660.CN)](https://longbridge.com/en/quote/510660.CN.md)

## Related News & Research

- [Assessing BioArctic (OM:BIOA B) Valuation After New Lecanemab Data And Regulatory Milestones](https://longbridge.com/en/news/281644038.md)
- [Biocytogen and Sihuan partner to advance new therapeutics for weight loss](https://longbridge.com/en/news/281501537.md)
- [Seres Group Refines AGM Agenda With Detailed Share Buyback Resolutions](https://longbridge.com/en/news/281431575.md)
- [Xinhua Pharma Becomes Marketing Authorization Holder of Dental Drug After Regulatory Nod](https://longbridge.com/en/news/281343251.md)
- [Sunho Biologics Flags Audit Delays as Auditor Seeks More Documentation](https://longbridge.com/en/news/280992698.md)